| 书目名称 | PI3K-mTOR in Cancer and Cancer Therapy |
| 编辑 | Nandini Dey,Pradip De,Brian Leyland-Jones |
| 视频video | |
| 概述 | Provides a comprehensive review of recent developments made in the basic science and the exciting new therapeutic strategies of the PI3K-mTOR pathway-related signal transduction.Examines the contribut |
| 丛书名称 | Cancer Drug Discovery and Development |
| 图书封面 |  |
| 描述 | In the post human-genome project era, cancer specific genomic maps are redesigning tumor taxonomy by evolving from histopathology to molecular pathology. The success of a cancer drug today is fundamentally based on the success in identifying target genes that control beneficial pathways. The overwhelming power of genomics and proteomics has enlightened researchers about the fact that the PI3K-mTOR pathway is the most commonly up-regulated signal transduction pathway in various cancers, either by virtue of its activation downstream of many cell surface growth factor receptors or by virtue of its collateral and compensatory circuitry with RAS-MAPK pathway. Oncogenic signaling in the majority of solid tumors is sustained via the PI3K-AKT-mTOR pathway. Because of its prominent role in many cancer types, the PI3K-mTOR pathway has become a major therapeutic target. The volume includes two complementary parts which address the problem of etiology and disease progression and is intended to portray the very basic mechanisms of the PI3K-AKT-mTOR signaling pathway’s involvement in various facets of the cancer, including stem cell renewal, cell metabolism, angiogenesis, genetic instability, an |
| 出版日期 | Book 2016 |
| 关键词 | apoptosis; cancer; cancer metabolism; drug development; drug resistance; signaling pathway; antibacterial |
| 版次 | 1 |
| doi | https://doi.org/10.1007/978-3-319-34211-5 |
| isbn_softcover | 978-3-319-81704-0 |
| isbn_ebook | 978-3-319-34211-5Series ISSN 2196-9906 Series E-ISSN 2196-9914 |
| issn_series | 2196-9906 |
| copyright | Springer Science+Business Media New York 2016 |
发表于 2025-3-21 17:49:21
